- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05740839
Exercício Intervalado de Alta Intensidade em Jovens Adultos Sobreviventes de Tumores Cerebrais Pediátricos: Um Estudo Piloto de Viabilidade (HYPE)
Exercício Intervalado de Alta Intensidade em Jovens Adultos Sobreviventes de Tumores Cerebrais Pediátricos: Um Estudo Piloto de Viabilidade (HYPE)
The purpose of this study is to determine whether a 16-week virtual, home-based, high-intensity interval training (HIIT) exercise program will improve physical, cognitive, and emotional health among young adult survivors of pediatric brain tumors.
The names of the study interventions involved in this study are/is:
- High-Intensity Interval Training (HIIT)
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This is a Pilot/Feasibility, randomized control, research study that will compare an exercise group to a control group on physical, social, and overall quality of life needs of pediatric brain tumor survivors who are now young adults.
Participants will be randomized (selected at random) for two groups: HIIT program group will complete a 16-week intervention period followed by a 16-week period with no intervention and the waitlisted control group will complete a 16-week period and will perform their usual, daily activities followed by an optional 16-week period in which they can complete the HIIT program.
Research procedures include screening for eligibility, study treatment including in-clinic evaluations of fitness and strength, blood collection, at-home zoom exercise sessions, self-administered activity logs, and survey questionnaires.
Participation in this research study is expected to last about 8 months.
It is expected that about 30 people will take part in this research study.
The Stahl Family Charitable Foundation, Pedal 4 Pediatrics, and the Childhood Brain Tumor Foundation are supporting this research study by providing funding for the study.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Christina Dieli-Conwright, PhD, MPH
- Número de telefone: 617-582-8321
- E-mail: ChristinaM_Dieli-Conwright@dfci.harvard.edu
Locais de estudo
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Recrutamento
- Dana Farber Cancer Institute
-
Contato:
- Christina M Dieli-Conwright, PhD, MPH
- Número de telefone: 617-632-3800
- E-mail: ChristinaM_Dieli-Conwright@dfci.harvard.edu
-
Investigador principal:
- Christina M Dieli-Conwright, PhD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Written informed consent prior to any study-related procedures.
- At time of study are a young adult, aged 18-45 years.
- Histologically diagnosed brain tumor during childhood, or currently diagnosed with an IDH-mutant glioma (diagnosed > 18 years).
- Are at least 2 years post tumor-directed therapy for pediatric brain tumor survivors, or at least 1 year since their most recent surgery, radiation or chemotherapy treatment for IDH-mutant glioma patients (or are deemed able to participate in the study based on the assessment of their treating physician). IDH-mutant glioma patients can participate while on maintenance therapy with an IDH inhibitor.
- The effects of exercise on the developing fetus are unknown. For this reason, people of child-bearing potential must verify pregnancy status by providing first day of their last menstrual cycle and agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry. Should a person become pregnant or suspect that they are pregnant while participating on the trial, they should inform their treating physician immediately.
- Medically cleared to participate in exercise by their referring physician or a certified clinical exercise physiologist.
- If participants have a diagnosis of tumor-related epilepsy, they must have good seizure control, with no generalized seizures in the 6 months preceding enrollment.
- Are without any other medical conditions that could exacerbate with exercise, such as bone disease (excluding bone metastases) at imminent risk of fracture or uncontrolled cardiopulmonary or metabolic diseases.
- Speak English and/or Spanish.
- Currently participate in less than or equal to 60 minutes of moderate or vigorous structured exercise/week.
- Does not smoke cigarettes or e-cigarettes (no smoking during the previous 12 months). Those who infrequently smoke in social settings will be included. Those who vape will also be included.
- Willing to travel to DFCI for necessary data collection.
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Diagnosis of primary spinal cord tumor.
- Pre-existing medical conditions such as uncontrolled tumor-related epilepsy, cardiopulmonary disease, or metabolic diseases that could exacerbate with exercise.
- Patients with evidence of progressive CNS or systemic cancer in the last 3 months.
- People who are pregnant, or plan to become pregnant during study duration will be excluded due to the unknown nature of exercise on developing fetuses.
- Actively on a weight loss diet.
- Participate in more than 60 minutes of moderate or vigorous structured exercise/week.
- Currently and regularly smokes.
- Unable to travel to DFCI for necessary data collection.
- May not be able to comply with the safety monitoring requirements of the study in the opinion of the investigator.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: HIIT Exercise Program Group
Participants will be randomly assigned to the HIIT exercise group and receive:
|
Exercise program with stationary bike via the Zoom platform.
Outros nomes:
|
|
Comparador Ativo: Control Group
Participants will be randomly assigned to the HIIT waitlist control group and receive:
|
Usual Activities |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Attendance of Exercise Sessions
Prazo: From first exercise session to final exercise session, up to 16 weeks
|
Defined as participant attendance of >= 70% of the 48 HIIT exercise sessions. |
From first exercise session to final exercise session, up to 16 weeks
|
|
Completion in Minutes of Exercise Sessions
Prazo: From first exercise session to final exercise session, up to 16 weeks
|
Defined as participant completion of >= 70% of the 90 minutes of exercise per week |
From first exercise session to final exercise session, up to 16 weeks
|
|
HIIT Compliance
Prazo: From first exercise session to final exercise session, up to 16 weeks
|
Defined as obtaining +-5W of target power output for >= 40 seconds of high intensity minute |
From first exercise session to final exercise session, up to 16 weeks
|
|
Barriers to Exercise Adherence
Prazo: From first exercise session to final exercise session, up to 16 weeks
|
Assessed through the 17-item Barriers to Recruitment Participation Questionnaire (BRPQ), 1-5 scale with 1 denoted as strongly agree and 5 as strongly disagree. |
From first exercise session to final exercise session, up to 16 weeks
|
|
Participant Burden
Prazo: From first exercise session to final exercise session, up to 16 weeks
|
Assessed through the Perceived Research Burden Assessment (PRBA), 1-5 scale with 1 denoted as strongly disagree and 5 as strongly agree. |
From first exercise session to final exercise session, up to 16 weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Cognition
Prazo: : From baseline to post-intervention, up to 43 weeks
|
An assortment of tests will be executed through the NIH toolbox to measure overall cognition. |
: From baseline to post-intervention, up to 43 weeks
|
|
Cardiorespiratory Fitness
Prazo: From baseline to post-intervention, up to 43 weeks
|
Assessed through the use of a VO2 max (or submaximal if equipment is unavailable) cycle exercise stress test (Parvo Medics TrueOne 2400; Sandy, UT, USA). |
From baseline to post-intervention, up to 43 weeks
|
|
Muscular Strength
Prazo: From baseline to post-intervention, up to 43 weeks
|
10-repetition maximum will be used to assess muscular strength. |
From baseline to post-intervention, up to 43 weeks
|
|
Body Composition
Prazo: From baseline to post-intervention, up to 43 weeks
|
Bioelectrical Impedance Analysis (BIA), and blood pressure as measured twice on both arms with a seated position with a minimum of 1-minute interval and the higher pressure will be recorded when there are differences. BIA: Assessed via bioelectrical impedance using a validated device (Tanita 780, Arlington Heights, IL). Participants will be asked to remove their shoes and socks after which height will be taken using a stadiometer they will then proceed to move to the BIA and stand still on the device while holding the handles with their hands at their sides. The device will estimate body fat using an algorithm based on their age, sex, height, and body weight. |
From baseline to post-intervention, up to 43 weeks
|
|
Fatigue
Prazo: From baseline to post-intervention, up to 43 weeks
|
BFI: A questionnaire of scale ratings 0 - 10 that focuses on cancer-related fatigue and tiredness. |
From baseline to post-intervention, up to 43 weeks
|
|
Psychosocial Health
Prazo: From baseline to post-intervention, up to 43 weeks
|
Assessed through the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire, which is comprised of 27 items with scale ratings validated to measure physical, emotional, social, and functional well-being of cancer patients and survivors |
From baseline to post-intervention, up to 43 weeks
|
|
Quality of Sleep
Prazo: From baseline to post-intervention, up to 43 weeks
|
Assessed through the Pittsburg Sleep Quality Index (PSQI), which is used to measure 7 components of the quality and patterns of sleep in participants. |
From baseline to post-intervention, up to 43 weeks
|
|
Dietary Assessment, ASA-24
Prazo: Up to 3 days
|
Participants will be provided with a login to enter dietary data measured by an automated, online self-administered 24-hour assessment tool. |
Up to 3 days
|
|
ActiGraph - Physical Activity Monitoring
Prazo: From baseline to post-intervention, up to 27 weeks
|
Participants will be provided with an accelerometer (ActiGraph, Pensacola, FL) to wear for seven days at baseline and post-intervention testing visits and will be instructed to wear the water-resistant accelerometer at all times except for when swimming or bathing. The device will record activity data and will be electronically transferred to a computer via USB cable at time of completion. |
From baseline to post-intervention, up to 27 weeks
|
|
Exercise Tolerance
Prazo: From baseline to week 16, up to 32 weeks
|
Will be recorded using the Exercise-Induced Feeling Inventory (EIF). Based on a 0-4 scale, it assesses the participant's feeling state change(s) post-exercise and is also used for the assessment of self-motivation to adhere to an exercise regimen. Participants will be asked to complete the inventory before and after each exercise session. |
From baseline to week 16, up to 32 weeks
|
|
Pain Index
Prazo: From baseline to post-intervention, up to 43 weeks
|
BPI: A 9 item questionnaire to evaluate the severity of pain and the impact of pain on the participant's daily functioning. |
From baseline to post-intervention, up to 43 weeks
|
|
Hip and Waist Circumference
Prazo: From baseline to post-intervention, up to 43 weeks
|
Hip and waist circumference will be assessed and recorded in cm. |
From baseline to post-intervention, up to 43 weeks
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Christina Dieli-Conwright, PhD, MPH, Dana-Farber Cancer Institute
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Atividade motora
- Movimento
- Fenômenos fisiológicos musculoesqueléticos
- Fenômenos fisiológicos musculoesqueléticos e neurais
- Técnicas de investigação
- Design de pesquisa epidemiológica
- Métodos epidemiológicos
- Design de pesquisa
- Métodos
- Condicionamento físico, humano
- Exercício
- Grupos de controle
- Treinamento intervalado de alta intensidade
Outros números de identificação do estudo
- 22-505
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Prazo de Compartilhamento de IPD
Data can be shared no earlier than 1 year following the date of publication
Critérios de acesso de compartilhamento IPD
Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .